ReviewFrontiers in pharmacology2025
Therapeutic potential of traditional Chinese medicine in pancreatic fibrosis: mechanisms of TCM formulas and active ingredients.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic fibrosis (PF), the primary pathological hallmark of chronic pancreatitis (CP), is recognized as a pivotal driver of CP progression. Currently, no therapies are approved by the U.S. Food and Drug Administration (FDA) specifically for PF treatment, highlighting an urgent need for novel therapeutic strategies. Emerging evidence positions Traditional Chinese Medicine (TCM) as a promising multi-target approach against PF. This paper summarizes the pathogenesis of PF and provides a detailed review and comprehensive analysis of the mechanisms underlying Chinese herbal formulas and active ingredients investigated for PF prevention and treatment in existing experimental studies. Numerous studies indicate that TCM combats PF by inhibiting pancreatic stellate cells (PSCs) activation, regulating extracellular matrix (ECM) breakdown, suppressing macrophage infiltration and polarization, and inhibiting pancreatic acinar cell apoptosis. Current basic research predominantly focuses on PSC activation and associated signaling pathways, particularly key pathways such as TGF-β/Smad, MAPK, NF-κB, and Hedgehog. This work thus offers novel insights and approaches for PF treatment and further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.